Diagnostics - Global - World Health Organization (WHO) Diagnostics are important to ensure quality, comprehensive and integrated primary health care and health services everywhere and for everyone Every medical decision depends on a proper diagnosis, and while diagnostics results influence approximately 70% of healthcare decisions, only 3–5% of healthcare budgets go to diagnostic services
Landscape analysis of commercially available and pipeline in vitro . . . (iii) establish research and development (R D) priorities that could help meet the identified gaps and needs in these diagnostics products This report is part of the WHO's ongoing efforts to prioritize and coordinate global R D efforts to support the development and optimization of new diagnostics and platforms to tackle drug-resistant infections
In vitro diagnostics - Global - World Health Organization (WHO) In vitro diagnostics (IVDs) are tests that can detect disease, conditions and infections In vitro simply means ‘in glass’, meaning these tests are typically conducted in test tubes and similar equipment, as opposed to in vivo tests, which are conducted in the body itself
Strengthening diagnostics capacity - World Health Organization (WHO) Whilst approximately 70% of healthcare decisions are made based on diagnostic test results, only 3–5% of healthcare budgets go to diagnostic services In many countries clinicians don’t have access to basic diagnostic tools or laboratory tests needed to support patients When they are available, vast distances and isolated communities often make testing people extremely difficult
WHO publishes new Essential Diagnostics List and urges countries to . . . To address the lack of access to tests and testing services in multiple countries, WHO since 2018 has published a yearly essential diagnostics list (EDL), a basket of recommended in vitro diagnostics that should be available at point-of-care and in laboratories in all countries to increase timely and life-saving diagnoses The latest edition, published today, includes WHO-recommended COVID-19
WHO releases new list of essential diagnostics; new recommendations for . . . Updated biennially, the Essential Diagnostics List is intended to support national in vitro diagnostics policy development and to improve access to IVD testing and clinical laboratory services As well as informing national EDLs, it provides advice on prioritization of IVDs at different levels of the healthcare system
The diagnostics landscape for sexually transmitted infections This document highlights the diagnostics available now to support scale-up and expanded access to screening to meet the growing testing demands in low- and middle-income countries (LMICs)
WHO and FIND formalize strategic collaboration to drive universal . . . Geneva, Switzerland – 10 February 2020 – The World Health Organization (WHO) and the Foundation for Innovative New Diagnostics (FIND) announced today that a memorandum of understanding has been signed by the two organizations to formalize a strategic collaboration that will strengthen diagnosis in resource-poor countries by closing major diagnostic gaps at country level and bolstering
Diagnostic testing for SARS-CoV-2 - World Health Organization (WHO) This document provides interim guidance to laboratories and other stakeholders involved in diagnostics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) It covers the main considerations for specimen collection, nucleic acid amplification testing (NAAT), antigen (Ag), antibody (Ab) detection and quality assurance This document will be updated as new information becomes
Guidance for post-market surveillance and market surveillance of . . . Post-market surveillance is a set of activities conducted by manufacturers, to collect and evaluate experience gained from medical devices that have been placed on the market, and to identify the need to take any action Post-market surveillance is a crucial tool to ensure that medical devices continue to be safe and well performing, and to ensure actions are undertaken if the risk of